What do systematic reviews say?

HES vs placebo or no treatment

The review found no eligible studies for this question.

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intracervical vs combined intracervical and paracervical anaesthesia

The review found no eligible studies for this question.

• Pain relief for outpatient hysteroscopy 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antispasmodic plus NSAID vs paracervical anaesthesia

The review found no eligible studies for this question.

• Pain relief for outpatient hysteroscopy 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Transdermal beta‐estradiol gel vs placebo

• Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1086 participants
  Moderate

Oral beta‐estradiol vs placebo

• Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 433 participants
  Low

Transdermal beta‐estradiol patch vs placebo

Transdermal beta‐estradiol patch may leads to higher adverse effects Beta‐estradiol patch dose 0.10 mg/day compared with placebo (low certainty).

• Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
  OR 2.14 [1.29, 3.54]
  9 studies · 1822 participants
  Low

Intranasal beta‐estradiol vs placebo

Intranasal beta‐estradiol probably leads to higher adverse effects Intranasal beta‐estradiol 0.021 mg/day, 0.029 mg/day… compared with placebo (moderate certainty).

• Bioidentical hormones for women with vasomotor symptoms 2016 · Cochrane Headline outcomes only
  OR 1.96 [1.26, 3.03]
  1 study · 458 participants
  Moderate